Table 1.
Characteristics of patients in a study cohort: risk factor distribution and IPI analysis
| Risk factor | Number of cases n (%) |
|---|---|
| Age | |
| ≤60 y | 133 (59,64) |
| >60 y | 90 (40,36) |
| ECOG performance status | |
| <2 | 209 (93,72) |
| ≥2 | 14 (6,28) |
| Clinical stage according to Ann Arbor scale | |
| I/II | 73 (32,74) |
| III/IV | 150 (67,26) |
| Number of extranodal sites | |
| 0‐1 | 99 (44,39) |
| >1 | 124 (55,61) |
| Serum LDH activity | |
| N | 97 (43,50) |
| >N | 126 (56,50) |
| IPI | |
| 0 | 19 (8,52) |
| 1 | 47 (21,08) |
| 2 | 70 (31,39) |
| 3 | 50 (22,42) |
| 4 | 34 (15,25) |
| 5 | 3 (1,35) |
| IPI risk groups | |
| Low risk (L, IPI: 0‐1) | 66 (29,60) |
| Intermediate risk (I, IPI: 2‐3) | 120 (53,81) |
| High risk (H, IPI: 4‐5) | 37 (16,59) |